Canaccord Genuity Maintains a 'Hold' on Medicis (MRX); Taking A Deeper Look
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $18.99 -24.43%
Rating Summary:
4 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
4 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on Medicis (NYSE: MRX) price target of $36.00.
Analyst, Randall Stanicky, said, "We have taken a deeper look into our MRX views post the quarter, as well as a fresh look at our model. The stock has been more stable since last year’s SOLODYN concerns and the late-year Graceway acquisition, up 10% YTD, or slightly below the S&P500 (+12%). From here, the story comes down to execution as we think about (1) driving product growth (SOLODYN and Zyclara key swing products), (2) progressing the pipeline and (3) more business development productivity. While we understand where potential for upside could come from, visibility is still limited for now and we see fewer obvious catalysts to get excited about. We think earnings will be the primary stock driver from here and remain below consensus though we have made several adjustments to our model."
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $36.90 yesterday.
Analyst, Randall Stanicky, said, "We have taken a deeper look into our MRX views post the quarter, as well as a fresh look at our model. The stock has been more stable since last year’s SOLODYN concerns and the late-year Graceway acquisition, up 10% YTD, or slightly below the S&P500 (+12%). From here, the story comes down to execution as we think about (1) driving product growth (SOLODYN and Zyclara key swing products), (2) progressing the pipeline and (3) more business development productivity. While we understand where potential for upside could come from, visibility is still limited for now and we see fewer obvious catalysts to get excited about. We think earnings will be the primary stock driver from here and remain below consensus though we have made several adjustments to our model."
For an analyst ratings summary and ratings history on Medicis click here. For more ratings news on Medicis click here.
Shares of Medicis closed at $36.90 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MarineMax (HZO) PT Lowered to $35 at Stifel
- Tyler Tech (TYL) PT Raised to $500 at Oppenheimer
- TechnipFMC (FTI) PT Raised to $30 at BTIG
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Standard & Poor's, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
